Related Experiment Video
Updated: May 30, 2026
11:59
Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
Published on: September 6, 2017
Recent advances in β-thalassemias
Antonio Cao1, Paolo Moi, Renzo Galanello
1Biomedical and Biotechnology Department, University of Cagliari, Cagliari, Italy.
Pediatric Reports
|July 21, 2011
Summary
Beta-thalassemia, a genetic anemia, is managed through screening, bone marrow transplants, and improved clinical care. Advances in gene therapy and understanding modifier genes like BCL11A offer new hope for a cure.
Area of Science:
- Hematology
- Genetics
- Medical Research
Background:
- Beta-thalassemia is a prevalent inherited blood disorder causing reduced beta-globin chain production.
- It poses a significant global health challenge, particularly in temperate regions.
- Effective population screening and prenatal diagnosis programs have been implemented.
Purpose of the Study:
- To review advancements in beta-thalassemia management and treatment.
- To highlight the role of genetic modifiers in disease variability.
- To discuss emerging therapeutic strategies including gene therapy.
Main Methods:
- Review of clinical management strategies, including iron chelation and diagnostic methods.
- Analysis of genetic research on modifier genes (e.g., BCL11A, Myb) and their impact on HbF.
- Examination of outcomes from bone marrow transplantation and gene therapy trials.
Main Results:
- Oral iron chelators (e.g., deferiprone) and NMR diagnostics have improved patient quality of life.
- Genetic polymorphisms in BCL11A, Myb, and gamma-globin significantly influence clinical phenotypes.
- The first successful gene therapy trial in 2010 offers a potential cure for beta-thalassemia.
Conclusions:
- Significant progress has been made in managing beta-thalassemia, improving survival and quality of life.
- Understanding genetic modifiers is crucial for predicting disease severity and guiding treatment.
- Gene therapy represents a promising frontier for a definitive cure for beta-thalassemia.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
01:22iPS Cell Differentiation
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
01:22Bone Marrow Sampling and Transplants
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...